SCHEMBL23477458

SCHEMBL23477458

COP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1OP(=O)(O)OC[C@@H]1C[C@@H](OP(O)O)[C@H](n2cnc3c(=O)[nH]c(N)nc32)O1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FUT5 Q11128 1/20 0.58
▸ TGM2 P21980 1/20 0.54
▸ NT5E P21589 1/20 0.54
▸ F2 P00734 1/20 0.52
▸ KRAS P01116 8/20 0.50
▸ P2RY2 P41231 1/20 0.49
▸ P2RY4 P51582 1/20 0.49
▸ P2RY6 Q15077 1/20 0.49
▸ RNASEL Q05823 2/20 0.48
▸ IMPDH2 P12268 1/20 0.48
▸ IMPDH1 P20839 1/20 0.48
▸ DCPS Q96C86 1/20 0.47
▸ TAS1R3 Q7RTX0 1/20 0.47
▸ TAS1R1 Q7RTX1 1/20 0.47
▸ HINT1 P49773 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23477132 0.93 FUT5 (0.60) FUT5TGM2NT5EF2KRAS
SCHEMBL23477212 0.91 FUT5 (0.58) FUT5TGM2NT5EF2KRAS
SCHEMBL25552773 0.90 TGM2 (0.60) FUT5TGM2NT5EF2KRAS
SCHEMBL20762956 0.88 TGM2 (0.65) FUT5TGM2NT5EKRASP2RY2
SCHEMBL23477177 0.88 FUT5 (0.57) FUT5TGM2NT5EF2KRAS
SCHEMBL23477183 0.87 FUT5 (0.56) FUT5TGM2NT5EF2KRAS
SCHEMBL23477028 0.86 FUT5 (0.58) FUT5TGM2NT5EF2KRAS
SCHEMBL20763046 0.86 FUT5 (0.57) FUT5TGM2NT5EF2KRAS
SCHEMBL24771772 0.86 RNASEL (0.56) FUT5TGM2RNASEL
SCHEMBL23477159 0.86 RNASEL (0.56) FUT5TGM2RNASEL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS CHINOOK THERAPEUTICS, INC. 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS STING1, TLR9, TLR3 FUT5 1917/4885TGM2 1457/4885NT5E 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback